Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded on 24th August 1981, Alfacell is dedicated to the research and development of a family of proteins isolated
from the eggs of the leopard frog (Rana pipiens), which has the potential to create a new class of therapeutic
compounds for the treatment of cancer and other pathological conditions.
In 1987, Alfacell completed the molecular characterisation of P-30 protein, the first ribonuclease (RNase) to be isolated.
In October 1998, the US Adapted Names Council adapted the name ranpirnase for P-30 protein, which the company
has trademarked as Onconase.